Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 135Breast 18Genitourinary 14Thoracic 9Plasma cell 8Other hematologic neoplasm 8Myeloid 8Lymphoid 8Dermatologic 8CNS 8Sarcoma 6Gastrointestinal 6Endocrine 2Other solid neoplasm 1Other 1NET 1Head & Neck 1Classical hematology 1

Conditions

Leukemia, Myeloid, Acute 76Anemia, Refractory, with Excess of Blasts 72Myelodysplastic Syndromes 69Leukemia 54Precursor Cell Lymphoblastic Leukemia-Lymphoma 51Anemia 50Leukemia, Lymphocytic, Chronic, B-Cell 44Leukemia, Myelomonocytic, Chronic 42Lymphoma, Non-Hodgkin 41Multiple Myeloma 38Hodgkin Disease 36Myeloproliferative Disorders 34Primary Myelofibrosis 33Thrombocytopenia 32Leukemia, Myelogenous, Chronic, BCR-ABL Positive 32Lymphoma 31Neoplasms 29Anemia, Aplastic 29Congenital Abnormalities 27Anemia, Refractory 25Lymphoma, Follicular 23Lymphoma, Mantle-Cell 21Lymphoma, B-Cell, Marginal Zone 18Burkitt Lymphoma 18Lymphoma, Large B-Cell, Diffuse 17Leukemia, Myeloid, Chronic-Phase 17Venous Thromboembolism 16Lymphoma, Large-Cell, Immunoblastic 16Leukemia, Myeloid, Accelerated Phase 16Waldenstrom Macroglobulinemia 14

Interventions

talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma, Ovarian Epithelial × Classical hematology × Clear all
NCT01286987 2019-01-10

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Pfizer

Phase 1 Completed
113 enrolled 39 charts
BreastClassical hematologyGastrointestinalGenitourinaryGynecologicSarcomaThoracic

Fanconi Anemia, Complementation Group D1, Carcinoma, Ovarian Epithelial, Breast Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Sarcoma, Ewing, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡